Core Insights - Gain Therapeutics, Inc. presented a poster at the FENS Forum 2024, highlighting the positive effects of GT-02287 on cognitive performance and daily living activities in a mouse model of GBA1 Parkinson's disease [15][1][3] Group 1: Company Overview - Gain Therapeutics is a clinical-stage biotechnology company focused on discovering and developing next-generation allosteric small molecule therapies [19] - The company's lead drug candidate, GT-02287, is designed to treat GBA1 Parkinson's disease and is currently undergoing a Phase 1 clinical trial [19][3] Group 2: Drug Development and Mechanism - GT-02287 is an orally administered small molecule that acts as an allosteric protein modulator, restoring the function of the glucocerebrosidase (GCase) enzyme, which is impaired due to GBA1 gene mutations [3][19] - In preclinical studies, GT-02287 has shown to restore GCase function, reduce aggregated α-synuclein, decrease neuroinflammation, and improve both motor function and cognitive performance [3][1] Group 3: Research Findings - The study demonstrated that GT-02287 improved nest-building and motor performance in a GBA1-PD mouse model, indicating its potential to enhance complex behaviors related to cognitive function [1][3] - Biomarker changes, including reduced plasma neurofilament light chain (NfL) levels, were observed, supporting the drug's efficacy in neurodegeneration [3][1] Group 4: Future Directions - The company aims to evaluate GT-02287 in patients suffering from GBA1 Parkinson's disease, emphasizing the need for effective treatments for this chronic condition [8][15] - Gain Therapeutics is committed to engaging with the neuroscience community to further discuss its innovative approach to treating GBA1 Parkinson's disease [8][15]

A PDF of the poster presented at the FENS Forum 2024 conference is available on the Science & Technology section of the Company's website at https://www.gaintherapeutics.com/science-and-technology/posters. Forward Looking Statements Gain's lead program in Parkinson's disease has been awarded funding support from The Michael J. Fox Foundation for Parkinson's Research (MJFF) and The Silverstein Foundation for Parkinson's with GBA, as well "These data further confirm our conviction that GT-02287 can slow or st ...

About Gain Therapeutics, Inc. Leveraging AI-supported structural biology, proprietary algorithms, and supercomputer-powered physics-based models, the company's Magellan™ drug discovery platform can identify novel allosteric binding sites on disease-implicated proteins, pinpointing pockets that cannot be found or drugged with current technologies. Its AI and machine-learning tools and virtual screening capabilities leverage the emerging on-demand compound libraries covering vast chemical spaces of over five ...

BETHESDA, Md., June 25, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) ("Gain", or the "Company"), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced that the Company's Chief Financial Officer, Gene Mack, will participate in a fireside chat and host virtual one-on-one meetings at H.C. Wainwright's 5th Annual Neuro Perspectives Virtual Conference taking place June 27, 2024. Time: 7:00am E ...

Gain Therapeutics (NASDAQ:GANX) stock is falling on Friday following the pricing of its shares in a public offering. Gain Therapeutics is also offering underwriters the option of acquiring another 1,222,222 shares in this public offering. Titan Partners Group is acting as the sole bookrunner for this offering. With this public offering, Gain Therapeutics is increasing the total number of outstanding shares. Doing so dilutes the stakes of current investors in the biotechnology company. That's one reason why ...

BETHESDA, Md., June 13, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. ("Gain" or the "Company") (Nasdaq: GANX) today announced the pricing of an underwritten public offering of (i) 7,116,547 shares of its common stock at a public offering price of $1.35 per share and (ii) pre-funded warrants to purchase 1,031,602 shares of common stock in lieu of shares of common stock to certain investors. The pre-funded warrants will be immediately exercisable, and may be exercised at any time after their original issu ...

Titan Partners Group, a division of American Capital Partners, is acting as the sole bookrunner for the offering. Gain intends to use the net proceeds from the offering to continue clinical and nonclinical development of its lead product candidate GT-02287 for the treatment of neurodegenerative diseases including GBA1 Parkinson's disease and for general corporate purposes. About Gain Therapeutics, Inc. Gain's unique approach enables the discovery of novel, allosteric small molecule modulators that can resto ...

Gain intends to use the net proceeds from the offering to continue clinical and nonclinical development of its lead product candidate GT-02287 for the treatment of neurodegenerative diseases including GBA1 Parkinson's disease and for general corporate purposes. The final terms of the offering will depend on market and other conditions at the time of pricing, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. The securities de ...

BETHESDA, Md., June 13, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. ("Gain" or the "Company") (Nasdaq: GANX) today announced that it is proposing to offer and sell, subject to market conditions, shares of its common stock (or pre-funded warrants in lieu thereof) in an underwritten public offering. Gain expects to grant the underwriter a 30-day option to purchase up to an additional 15% of the shares of common stock and pre-funded warrants offered in the offering. All of the securities are being offered ...

Core Insights - Gain Therapeutics, Inc. announced that a late-breaking abstract on its drug candidate GT-02287 has been accepted for presentation at the FENS Forum 2024, highlighting cognitive performance improvements in a preclinical model of GBA1 Parkinson's disease [1][2] Company Overview - Gain Therapeutics is a clinical-stage biotechnology company focused on developing next-generation allosteric small molecule therapies [6] - The lead drug candidate, GT-02287, is designed to treat GBA1 Parkinson's disease and is currently in a Phase 1 clinical trial [6] Drug Candidate Details - GT-02287 is an orally administered, brain-penetrant small molecule that acts as an allosteric protein modulator, restoring the function of the lysosomal enzyme glucocerebrosidase (GCase) [4] - In preclinical models, GT-02287 has shown to restore GCase function, reduce aggregated α-synuclein, decrease neuroinflammation and neuronal death, increase dopamine levels, and improve both motor function and cognitive performance [4] - The drug also significantly reduced plasma neurofilament light chain (NfL) levels, which is an emerging biomarker for neurodegeneration [4] Funding and Support - Gain Therapeutics has received funding support from The Michael J. Fox Foundation for Parkinson's Research, The Silverstein Foundation for Parkinson's with GBA, and the Eurostars-2 joint program co-funded by the European Union Horizon 2020 research and Innosuisse [5] Research and Development Platform - The company utilizes its Magellan™ drug discovery platform, which leverages AI-supported structural biology and supercomputer-powered models to identify novel allosteric binding sites on disease-implicated proteins [7] - This platform enhances the original SEE-Tx® platform, allowing access to vast chemical spaces of over five trillion compounds for drug discovery [7][8]